John Butler, Akebia CEO
April 4, 2023 02:07 PM EDT
R&D
Pharma

Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

Katherine Lewin

News Reporter

Ake­bia Ther­a­peu­tics is back with more da­ta on its ex­per­i­men­tal ane­mia drug vadadu­s­tat fol­low­ing a CRL from the FDA last year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times